Regimen-related gastrointestinal toxicities in cancer patients

Current Opinion in Supportive and Palliative Care

Volumn 4, Issue 1, 2010, Pages 26-30

  Sonis, Stephen T ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Cancer; Chemotherapy; Mucositis; Radiation; Toxicity

Indexed keywords

ANTINEOPLASTIC AGENT;

CHEMICALLY INDUCED DISORDER; FEMALE; HUMAN; MALE; MUCOSA INFLAMMATION; PATHOPHYSIOLOGY; RADIOTHERAPY; REVIEW; RISK FACTOR;

ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; MALE; MUCOSITIS; RADIOTHERAPY; RISK FACTORS;

EID: 77950353795     PISSN: 17514258     EISSN: 17514266     Source Type: Journal    
DOI: 10.1097/SPC.0b013e328335fb76     Document Type: Article

References (25)

1. Keefe DM. Mucositis management in patients with cancer. Support Cancer Ther 2006; 3:154-157.
2. Gerullis H, Bergmann L, Mante L, et al. Experiences and practical conclusions concerning temsirolimus use and adverse event management in advanced renal cell carcinoma within a compassionate use program in Germany. Cancer Chemother Pharmacol 2009; 63:1097-1102.
3. Guevremont C, Alasker A, Karakiewicz PI. Management of sorafenib, sunitinib, and temsirolimus toxicity in metastatic renal cell carcinoma. Curr Opin Support Palliat Care 2009; 3:170-179.
4. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007; 25:1960-1966.
5. Aprile G, Ramoni M, Keefe D, et al. Application of distance martices to define associations between acute toxicities in colorectal cancer patients receiving chemotherapy. Cancer 2008; 112:284-292.
6. Sonis ST, Elting LS, Keefe D, et al. Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer 2004; 100 (9 Suppl):1995-2025.
7. Elting LS, Cooksley C, Chambers M, et al. The burdens of cancer therapy. Clinical and economic outcomes of chemotherapy-induced mucositis. Cancer 2003; 98:1531-1539.
8. Nonzee NJ, Dandade NA, Patel U, et al. Evaluating the supportive costs of severe radiochemotherapy-induced mucositis and pharyngitis: results from a Northwestern University Cost of Cancer Program pilot study with head and neck and nonsmall cell lung cancer patients who received care at a county hospital, a Veterans Administration hospital, or a comprehensive cancer center. Cancer 2008; 113:1446-1452.
9. Barasch A, Peterson DE. Risk factors for ulcerative oral mucositis in cancer patients: unanswered questions. Oral Oncol 2003; 39:91-100.
10. Blijlevens N, Schwenkglenks M, Bacon P, et al. Prospective oral mucositis audit: oral mucositis in patients receiving high-dose melphalan or BEAM conditioning chemotherapy - European Blood and Marrow Transplantation Advisory Group. J Clin Oncol 2008; 26:1519-1525.
11. Chansky K, Benedetti J, Macdonald JS. Differences in toxicity between men and women treated with 5-fluorouracil therapy for colorectal cancer. Cancer 2005; 103:1165-1171.
12. Chen E. Impact of preexisting psoriasis and Addison's disease on chemotherapy-induced mucositis in patients with hematological malignancies. Predoctoral thesis; 2004. Harvard School of Dental Medicine.
13. Schwab M, Zanger UM, Marx C, et al. Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU toxicity study group. J Clin Oncol 2008; 26:2131-2138.
14. Bogunia-Kubik K, Polak M, Lange A. TNF polymorphisms are associated with toxic, but not with aGVHD complications in the recipients of allogeneic sibling haematopoietic stem cell transplantation. Bone Marrow Transplant 2003; 32:617-622.
15. Ambrosone CB, Tian C, Ahn J, et al. Genetic predictors of acute toxicities related to radiation therapy following lumpectomy for breast cancer: a caseseries study. Breast Cancer Res 2006; 8:R40.
16. Stringer AM, Gibson RJ, Logan JM, et al. Gastrointestinal microflora and mucins may play a critical role in the development of 5-fluorouracil-induced gastrointestinal mucositis. Exp Biol Med 2009; 232:430-441.
17. Sonis ST. The pathobiology of mucositis. Nat Rev Cancer 2004; 4:277-284.
18. Logan RM, Stringer AM, Bowen JM, et al. Is the pathobiology of chemotherapy-induced alimentary tract mucositis influenced by the type of mucotoxic drug administered. Cancer Chemother Pharmacol 2009; 63:239-251.
19. Sonis ST. Mucositis: the impact, biology and therapeutic opportunities of oral mucositis. Oral Oncol 2009; 45:1015-1020.
20. Keefe DM, Schubert MM, Elting LS, et al. Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer 2007; 109:820-831.
21. Bensinger W, Schubert M, Ang KK, et al. NCCN Task Force Report. Prevention and management of mucositis in cancer care. J Natl Compr Canc Netw 2008; 6 (Suppl 1):1-21.
22. Spielberger R, Stiff P, Bensinger W, et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med 2004; 351:2590-2598.
23. Keefe DM, Sonis ST, Bowen JM. Emerging drugs for chemotherapy-induced mucositis. Exp Opin Emerg Drugs 2008; 13:511-522.
24. Barber C, Powell R, Ellis A, et al. Comparing pain control and ability to eat and drink with standard therapy vs gelclair: a preliminary, double center, randomised controlled trial on patients with radiotherapy-induced oral mucositis. Support Care Cancer 2007; 15:427-440.
25. Elting LS, Keefe DM, Sonis ST, et al. Patient-reported measurements of oral mucositis in head and neck cancer patients treated with radiotherapy with or without chemotherapy: demonstration of increased frequency, severity, resistance to palliation, and impact on quality of life. Cancer 2008; 113:2704-2713.